Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Advanced Solid Tumors
100%
Phase I Study
100%
Circulating Tumor DNA (ctDNA)
100%
MET Exon 14
100%
Tepotinib
100%
Overall Survival
80%
Progression-free Survival
60%
Non-responders
60%
MET Amplification
60%
Objective Response Rate
60%
Next-generation Sequencing
40%
Dysregulated
40%
MR-group
40%
Cancer Patients
20%
Antitumor Activity
20%
Seoul
20%
Tissue-like
20%
Tumor Protein p53 (TP53)
20%
Potential Biomarkers
20%
Disease Progression
20%
Mutated Genes
20%
Germany
20%
High Response Rate
20%
Positive Groups
20%
KRAS mutation
20%
Molecular Response
20%
Genetic Profile
20%
PIK3CA
20%
Site-directed mutation
20%
Darmstadt
20%
Solid Cancer
20%
Long Progression-free Survival
20%
Merck KGaA
20%
Radiological Response
20%
Oncogenic Alterations
20%
Advanced Cancer Patients
20%
Biomarker Analysis
20%
Clinical Trial Data
20%
BRAF Gene
20%
Next-generation Sequencing Data
20%
Variant Allele Frequency
20%
Liquid Biomarkers
20%
ERBB2 Gene
20%
MET Alterations
20%
Liquid-like
20%
During Treatment
20%
Advanced or Metastatic
20%
Medicine and Dentistry
Biological Marker
100%
Exon
100%
Cancer
100%
Tepotinib
100%
Chloroplast DNA
100%
Overall Survival
80%
Progression Free Survival
80%
Next Generation Sequencing
60%
Malignant Neoplasm
20%
Clinical Trial
20%
Disease Exacerbation
20%
Carcinogenesis
20%
Advanced Cancer
20%
Antineoplastic Activity
20%
Gene Frequency
20%
Genetics
20%
Immunology and Microbiology
Exon
100%
Blood Plasma
100%
Overall Survival
80%
Progression Free Survival
80%
Next Generation Sequencing
60%
Antineoplastic Activity
20%
Gene Frequency
20%